Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial

Background: Obesity is strongly associated with prevalence of obstructive sleep apnea (OSA), and weight loss has been shown to reduce disease severity. Objective: To investigate whether liraglutide 3.0 mg reduces OSA severity compared with placebo using the primary end point of change in apnea–hypop...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International Journal of Obesity 2016-08, Vol.40 (8), p.1310-1319
Hauptverfasser:	Blackman, A, Foster, G D, Zammit, G, Rosenberg, R, Aronne, L, Wadden, T, Claudius, B, Jensen, C B, Mignot, E
Format:	Artikel
Sprache:	eng
Schlagworte:	631/92/436/108 692/163 692/699/2743/393 692/699/375/1816 692/700/2817 692/700/565/1903 Adolescent Adult Anti-Obesity Agents - pharmacology Anti-Obesity Agents - therapeutic use Appetite depressants Blood pressure Body mass index Body weight Clinical medicine Clinical practice guidelines Clinical trials Complications and side effects Diabetes Double-Blind Method Drug dosages Drug therapy Epidemiology Exercise Female Glycated Hemoglobin A - metabolism Health Promotion and Disease Prevention Humans Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Internal Medicine Liraglutide Liraglutide - pharmacology Liraglutide - therapeutic use Male Medicine Medicine & Public Health Metabolic Diseases Middle Aged Obesity Obesity - complications Obesity - drug therapy Obesity - physiopathology Original original-article Physical fitness Polysomnography Prospective Studies Public Health Quality of life Sleep apnea Sleep apnea syndromes Sleep Apnea, Obstructive - complications Sleep Apnea, Obstructive - drug therapy Sleep Apnea, Obstructive - physiopathology Treatment Outcome United States - epidemiology Weight control Weight Loss - drug effects Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!